January 21, 2025
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
January 17, 2025
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)